LEXINGTON, Mass., Oct. 11, 2016 /PRNewswire/ -- Pulmatrix,
Inc. (NASDAQ: PULM) will present promising new preclinical data
about its inhaled antifungal drug PUR1900 in a poster at the North
American Cystic Fibrosis Conference.
"The preclinical study comparing PUR1900 to the oral reference
product shows that PUR1900 offers a significant advantage over the
current standard of care for treating fungal infections in the
lungs," said David Hava, Ph.D., Chief Scientific Officer for
Pulmatrix.
Cystic fibrosis patients frequently suffer from a condition
called allergic bronchopulmonary aspergillosis (ABPA), an allergic
disease caused by fungal infections, which is often treated with
oral antifungals, such as itraconazole. High oral doses are needed
to get enough of the antifungal drug to the lungs through the
bloodstream to fight the infection, resulting in the potential for
severe side effects that must be managed and monitored—including
liver toxicity.
Pulmatrix's inhaled drug PUR1900, which combines itraconazole
with the company's dry powder delivery technology platform, has the
potential to solve these problems by delivering the drug directly
to the lungs. The new study confirms the expected advantages of
inhaled drug delivery.
"The profile of PUR1900 demonstrated in this study, with high
lung exposure and low systemic levels, should be well suited for
treating fungal infections. Our goal is to translate this
profile in our upcoming clinical trials which will help us
establish optimal dosing parameters for patients," explained Dr.
Hava.
The poster will be presented during the conference in the
Orange County Convention Center in
Orlando, Florida, October 27-29.
About
Pulmatrix
Pulmatrix is a clinical stage biopharmaceutical company
developing innovative inhaled therapies to address serious
pulmonary disease using its patented iSPERSE™ technology. The
Company's proprietary product pipeline is focused on advancing
treatments for lung diseases, including opportunities in
major pulmonary diseases through collaborations, like PUR0200, a
branded generic in clinical development for chronic obstructive
pulmonary disease (COPD) and PUR1900, an inhaled antifungal that
could benefit severe asthmatics and patients with rare disease like
cystic fibrosis. Pulmatrix's product candidates are based on
iSPERSE™, its proprietary dry powder delivery platform, which seeks
to improve therapeutic delivery to the lungs by maximizing local
concentrations and reducing systemic side effects to improve
patient outcomes.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release that are
forward-looking and not statements of historical fact are
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The Company cautions that such statements involve risks and
uncertainties that may materially affect the Company's results of
operations. Such forward-looking statements are based on the
beliefs of management as well as assumptions made by and
information currently available to management. Actual results could
differ materially from those contemplated by the forward-looking
statements as a result of certain factors, including but not
limited to the ability to establish that potential products are
efficacious or safe in preclinical or clinical trials; the ability
to establish or maintain collaborations on the development of
therapeutic candidates; the ability to obtain appropriate or
necessary governmental approvals to market potential products; the
ability to obtain future funding for developmental products and
working capital and to obtain such funding on commercially
reasonable terms; the Company's ability to manufacture product
candidates on a commercial scale or in collaborations with third
parties; changes in the size and nature of competitors; the ability
to retain key executives and scientists; and the ability to secure
and enforce legal rights related to the Company's products,
including patent protection. A discussion of these and other
factors, including risks and uncertainties with respect to the
Company, is set forth in the Company's annual report on Form 10-K
filed by the Company with the Securities and Exchange Commission on
March 10, 2016. The Company disclaims
any intention or obligation to revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by law.
Investor Contact
Robert
Clarke, CEO
(781) 357-2333
rclarke@pulmatrix.com
William Duke, CFO
(781) 357-2333
wduke@pulmatrix.com
Chris Brinzey, Westwicke
Partners
(339) 970-2843
IR@pulmatrix.com
Logo -
http://photos.prnewswire.com/prnh/20150616/223308LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/pulmatrix-will-present-promising-new-data-at-the-north-american-cystic-fibrosis-conference-on-october-27-29-2016-300341644.html
SOURCE Pulmatrix, Inc.